Fludeoxyglucose F 18 Injection
The Fludeoxyglucose F 18 Injection (fdg) safety database for epilepsy included of 374 patients. Of these, 245 were male and 105 were female. For 24 patients, gender was not specified. The mean age was 47.8 years (range under 2 to over 65 years). Eighteen patients were between the age of 0 and 2 years; 42 patients were between the ages of 2 and 21 years; 213 patients were between 21 and 65 years; 98 patients were older than 65 years; and the ages of 3 male patients were not specified. A racial distribution is not available. In this database, adverse drug reactions that required medical intervention were not reported. In a small, 42 patient subset of the 374 patients studied, 4 patients had transient hypotension, 6 had hypo- or hyperglycemia and 3 had transient increases in alkaline phosphatase.
Reviews of the oncology and cardiology literature did not reveal reported adverse reactions.
Read the Fludeoxyglucose F 18 Injection (fdg) Side Effects Center for a complete guide to possible side effects »
No information provided.
Last reviewed on RxList: 9/15/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Fludeoxyglucose F 18 Injection Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.